F11R and breast carcinoma: Downregulation of JAM-A was proposed to lead to inhibition of Bcl-2 and extracellular signal-regulated kinases (ERK), in turn resulting in suppression of proliferation and caspase-dependent apoptosis in breast cancer cells (Figure 9) [94].